Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06188585 · ClinicalTrials.gov registry record · NA
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding
A NA study of Acute Gastrointestinal Bleeding, sponsored by Medtronic - MITG.
- Recruiting
- Registry status
- NA
- Development phase
- 278
- Enrollment target
- 15
- Study locations
NCT06188585 is a NA study of Acute Gastrointestinal Bleeding that is actively recruiting participants, run by Medtronic - MITG. The registered enrollment target is 278 participants. The trial reports 15 study locations across 8 states.
The verdict
NCT06188585, a NA study of Acute Gastrointestinal Bleeding, is actively recruiting participants, sponsored by Medtronic - MITG.
- RECRUITING
- Registry status
- NA
- Development phase
- 278 participants
- Enrollment target
- 15
- Study locations
Study Summary
A prospective, multi-center, noninferiority randomized controlled trial designed to compare the efficacy of UI-EWD (Nexpowder™) hemostatic powder versus conventional endoscopic hemostatic therapy in patients presenting with acute overt gastrointestinal bleeding which is found at endoscopy to be due to one of the following sources: a gastric or duodenal ulcer with active bleeding (spurting or oozing) or a non-bleeding visible vessel; an esophageal, gastric or duodenal tumor with active bleeding or a non-bleeding visible vessel; a gastric or duodenal Dieulafoy lesion with active bleeding or a non-bleeding visible vessel; or an actively bleeding Mallory-Weiss tear.
Conditions Studied
Interventions
- DEVICE UI-EWD
- DEVICE Conventional therapy
Study Locations (15)
Other
- St. Michael's Hospital - Toronto
- Vancouver General Hospital - Vancouver
- Copenhagen University Hospital - Hvidovre
- Odense University Hospital - Odense
- St. Antoine - Paris
- Emek Medical Center - Afula
- Cleveland Clinic London - London
New York
- Northwell Health - Manhasset
- NYU Langone - New York
Alabama
- University of Alabama - Birmingham
Connecticut
- Yale - New Haven
Illinois
- RUSH University - Chicago
Massachusetts
- Brigham and Women's Hospital - Boston
New Jersey
- Rutgers University - Piscataway
Quebec
- McGill University - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2026-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06188585
The ClinicalTrials.gov registry entry for NCT06188585 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 278 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic - MITG, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Gastrointestinal Bleeding appearing as the primary indexed condition, and to 2 interventions - of which UI-EWD is the first listed.
NCT06188585 reports 15 study locations spanning 8 distinct geographic areas - top geographies include Other, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT06188585 about?
NCT06188585 is a clinical study titled "Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding". A prospective, multi-center, noninferiority randomized controlled trial designed to compare the efficacy of UI-EWD (Nexpowder™) hemostatic powder versus conventional endoscopic hemostatic therapy in patients presenting with acute overt gastrointestinal bleeding which is found at endoscopy to be due ...
What is the current status of trial NCT06188585?
This trial is currently recruiting. It is a NA study. The enrollment target is 278 participants. The study started on 2024-06-21. Estimated completion is 2026-08.
What conditions does trial NCT06188585 study?
This clinical trial studies the following conditions: Acute Gastrointestinal Bleeding.
What interventions are being tested in trial NCT06188585?
The interventions under investigation include: UI-EWD (DEVICE), Conventional therapy (DEVICE).
Who is sponsoring clinical trial NCT06188585?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06188585 being conducted?
This trial has 15 study locations across Alabama, Connecticut, Illinois, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.